drugset / Trial / NCT01137604
A Study in Subjects With Recurrent Malignant Glioma
RandomizedParallel-groupOpen-labelTreatment
Summary
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
Timeline
- Start
- 2010-11-09
- Primary completion
- 2013-03-19
- Completion
- 2014-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |